Table 2 Treatment response and pathological staging in Helicobacter pylori–stratified neoadjuvant immunotherapy and chemotherapy patients
Variable | Chemo-immunotherapy H. pylori | Chemotherapy H. pylori | ||||||
|---|---|---|---|---|---|---|---|---|
Total (n = 86) | Negative (n = 53) | Positive (n = 33) | P | Total (n = 115) | Negative (n = 79) | Positive (n = 36) | P | |
TRG | 0.993 | 0.835 | ||||||
MjHR | 39 | 24 (45.28) | 15 (45.45) | 29 | 19 (24.05) | 10 (27.78) | ||
PHR | 23 | 14 (26.42) | 9 (27.27) | 46 | 33 (41.77) | 13 (36.11) | ||
NHR | 24 | 15 (28.30) | 9 (27.27) | 40 | 27 (34.18) | 13 (36.11) | ||
ORR | 0.187 | 0.090 | ||||||
CR/PR | 47 | 26 (49.06) | 21 (63.64) | 60 | 37 (46.84) | 23 (63.89) | ||
SD/PD | 39 | 27 (50.94) | 12 (36.36) | 55 | 42 (53.16) | 13 (36.11) | ||
pCR | 0.627 | 0.866 | ||||||
pCR | 21 | 12 (22.64) | 9 (27.27) | 12 | 9 (11.39) | 3 (8.33) | ||
Non-pCR | 65 | 41 (77.36) | 24 (72.73) | 103 | 70 (88.61) | 33 (91.67) | ||
MPR | 0.795 | 0.912 | ||||||
MPR | 38 | 24 (45.28) | 14 (42.42) | 28 | 19 (24.05) | 9 (25.00) | ||
Non-MPR | 48 | 29 (54.72) | 19 (57.58) | 87 | 60 (75.95) | 27 (75.00) | ||
ypTNM | 0.541 | 0.579 | ||||||
I | 42 | 24 (45.28) | 18 (54.55) | 31 | 20 (25.32) | 11 (30.56) | ||
II | 15 | 11 (20.75) | 4 (12.12) | 31 | 20 (25.32) | 11 (30.56) | ||
III | 29 | 18 (33.96) | 11 (33.33) | 53 | 39 (49.37) | 14 (38.89) | ||
Pathological tumor stage (ypT) | 0.656 | 0.449 | ||||||
0–1 | 38 | 22 (41.5) | 16 (48.5) | 21 | 13 (16.5) | 8 (22.2) | ||
2–4 | 24 | 31 (58.5) | 17 (51.5) | 94 | 66 (83.5) | 28 (77.8) | ||
Pathological node stage (ypN) | 0.652 | 0.313 | ||||||
0 | 51 | 30 (56.60) | 21 (63.64) | 49 | 31 (39.24) | 18 (50.00) | ||
1–3 | 35 | 23 (43.40) | 12 (36.36) | 66 | 48 (60.76) | 18 (50.00) | ||